Could less be more? kidney transplant study tests lower drug dose to save kidney function
NCT ID NCT00213590
First seen Jun 08, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This study tested whether giving kidney transplant patients a lower dose of the anti-rejection drug cyclosporine A (combined with another drug, mycophenolate mofetil) could better protect their kidney function over time. The trial involved 208 adults who were at least one year post-transplant and had stable kidney function. Researchers measured kidney function after two years to see if the lower dose helped prevent further kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de ROUEN
Rouen, 76031, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclosporine A (a drug that suppresses the immune system to prevent organ rejection)
What this could lead to
If successful, this could show that using less cyclosporine A helps protect kidney function in transplant recipients while still preventing rejection.
What could go wrong
This is a completed phase 3 trial, so results are available but may not apply to all patients. Lowering immunosuppression always carries a risk of organ rejection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.